NEW YORK (GenomeWeb News) – Dubai, UAE-based Eastern Biotech said today that it has signed an agreement to promote Decode Genetics’ DNA-based tests for diabetes and other diseases in the Middle East.
The firm, which also runs a clinical reference lab, said that it would offer Decode’s tests for assessing risk of type 2 diabetes, myocardial infarction, atrial fibrillation, prostate cancer, glaucoma, breast cancer, and other tests currently under development by Decode.
Further terms of the alliance were not disclosed.